Join Us

We are 224,438 members in 83 forums discussing 163,551 topics.

Help with Abbreviations

Topic: The DESTINY-Breast05 trial is enrolling - learn more here!

Forum: Clinical Trials, Research News, Podcasts, and Study Results —

Share your research articles, interpretations and experiences here. Let us know how these studies affect you and your decisions.

Posted on: Jul 29, 2021 03:23PM

Moderators wrote:

The DESTINY-Breast05 trial is enrolling people diagnosed with HER2-positive breast cancer without a pathologic complete response from treatment before surgery.

The trial is looking to see whether fam-trastuzumab-deruxtecan-nxki reduces recurrence risk more than Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine) when given after surgery for HER2-positive breast cancer that didn't have pCR.

Fam-trastuzumab-deruxtecan-nxki is given by intravenous infusion, which means the medicine is delivered directly into your bloodstream through an IV or a port. The medicine is usually given once every 3 weeks.

People are eligible for the DESTINY-Breast05 trial if:

  • they are a legal adult in their country and have been diagnosed with HER2-positive breast cancer
  • the cancer has been treated before surgery with neoadjuvant chemotherapy and an anti-HER2 medicine
  • the cancer has not achieved pCR

The DESTINY-Breast05 trial is being conducted at multiple sites around the world and the United States. For a complete list of sites, visit

For more information on detailed eligibility requirements or to enroll

To send a Private Message to the Mods: